Bakuchiol Matched Retinol in the Only Head-to-Head Clinical Trial. With Less Irritation.

Retinol is the most studied topical active in skincare. Decades of clinical trials. Thousands of published papers. No credible dispute about its capacity to reduce wrinkles, stimulate collagen, and accelerate cell turnover.

And yet most people who start using retinol stop within the first month.

The reason is not complicated. Retinol works, but it also causes scaling, stinging, redness, and peeling. In clinical literature, this is documented as "retinoid dermatitis." In practice, it means a product sitting unused in a bathroom cabinet because the side effects felt worse than the skin concern it was meant to address.

Dr Alison Jamieson, Cosmetic Physician, has observed this pattern across four decades of clinical practice in Queensland. The efficacy of retinol was never in question. The compliance problem was. That is why the Ultimate A Night Cream was formulated with both retinol and bakuchiol, not one or the other. The clinical rationale sits on a single landmark study.

The Dhaliwal Trial: The Only Direct Comparison

In 2019, researchers at UC Davis published a randomised, double-blind clinical trial in the British Journal of Dermatology. It remains the only head-to-head comparison of bakuchiol and retinol ever conducted.

The study enrolled 44 patients. One group applied 0.5% bakuchiol twice daily. The other applied 0.5% retinol once daily. Both groups were assessed over 12 weeks using standardised photographic grading for wrinkles and pigmentation.

The results were striking. On every efficacy measure, there was no statistically significant difference between the two groups. Both achieved approximately 20% wrinkle reduction. For pigmentation, bakuchiol performed slightly better: 59% of the bakuchiol group showed improvement compared to 44% in the retinol group.

Where the difference became clinically significant was tolerability. The retinol group reported more scaling and stinging at every assessment point throughout the 12-week trial. The bakuchiol group experienced none of the characteristic irritation associated with retinoid use.

Different Molecules, Different Pathways

What makes this result possible is that bakuchiol and retinol are fundamentally different molecules working through different biological mechanisms.

Retinol is a retinoid. It binds to retinoid receptors (RAR and RXR) in the skin, directly modulating gene expression to accelerate cell turnover and stimulate collagen synthesis. This is a powerful mechanism, but it is also the source of the irritation: the same receptor activation that drives renewal also triggers the inflammatory response that causes scaling and sensitivity.

Bakuchiol is a meroterpene phenol, originally derived from the seeds of Psoralea corylifolia and used in Ayurvedic and traditional Chinese medicine for thousands of years. It does not bind to retinoid receptors. Instead, it targets mitochondrial proteins called prohibitins, which regulate cell proliferation, differentiation, and apoptosis through a separate signalling cascade.

The practical implication: bakuchiol achieves retinol-like outcomes on wrinkles and pigmentation without activating the receptor pathway that causes retinoid dermatitis. It delivers similar functional results through different biological machinery.

The Stabilisation Effect

There is a second reason to pair these two ingredients rather than choose one over the other.

Retinol is notoriously unstable. It degrades rapidly on exposure to light, air, and even the skin's own enzymes. Standard free-form retinol delivers a burst of activity on application, then breaks down within hours. Much of what you apply never reaches the target cells in a functional state.

Research on bakuchiol has demonstrated that at a 4:1 ratio of bakuchiol to retinol, bakuchiol completely prevents retinol from degrading through photodecomposition. It acts as a molecular stabiliser, extending retinol's active window and ensuring that more of the applied dose reaches the cells that need it.

The Ultimate A Night Cream uses precisely this 4:1 ratio. Combined with micro-encapsulation technology that controls retinol's release rate, the formulation delivers retinol at a sustained, lower concentration over the full overnight period rather than in a single peak. The result is a 9-fold increase in retinol's functional half-life compared to standard free-form delivery. More contact time with target cells. Lower peak irritation. Better outcomes from the same active.

Why Both, Not Either

The formulation logic is not about hedging. It is about covering two distinct biological pathways simultaneously.

Retinol drives renewal through retinoid receptor activation: accelerating cell turnover, stimulating collagen I and III, and suppressing the enzymes that break collagen down. Bakuchiol drives renewal through prohibitin-mediated pathways: supporting cell proliferation and differentiation without triggering the inflammatory cascade that makes retinol difficult to tolerate.

Together, they deliver a broader signal than either ingredient alone. The skin receives renewal instructions from two independent pathways while the irritation profile remains closer to bakuchiol's. And because bakuchiol stabilises retinol against degradation, the retinol that is present works harder and lasts longer.

This is protocol logic applied to formulation. Each ingredient addresses a limitation of the other.

Within the PM Protocol

The Ultimate A Night Cream occupies the final step of the PM Protocol, applied after cleansing and serum application. The timing is not arbitrary. Retinol is photosensitive and degrades under UV, making evening application essential. Skin's repair and renewal processes also peak during sleep, when cell division accelerates and collagen synthesis increases.

For those new to retinol, Dr Jamieson recommends a graduated introduction: twice weekly for the first fortnight, alternate nights for weeks three and four, then nightly from week five. The micro-encapsulated delivery and 4:1 bakuchiol ratio make this formulation substantially more tolerable than conventional retinol products, but gradual adaptation still supports the best outcomes with the least disruption.

The Biocinamide Serum, applied before the Night Cream, provides barrier reinforcement through ceramide stimulation and postbiotic support. A strong barrier tolerates active ingredients better. The two products are designed to work as a system, not in isolation.

What to Expect

Published data and clinical observation suggest this timeline for consistent nightly use.

Weeks one to two: smoother texture, improved morning hydration. The barrier and lipid base are doing their immediate work. Weeks two to four: visible brightening as accelerated cell turnover brings fresher cells to the surface. Fine lines begin to soften. Weeks four to eight: measurable wrinkle reduction and evening of skin tone as collagen stimulation and melanin regulation reach functional levels. Weeks eight to twelve: peak clinical results consistent with the Dhaliwal trial data, approximately 20% wrinkle reduction and 59% improvement in hyperpigmentation.

The compound effect of consistent use is where retinol delivers its real value. The formulation's tolerability is not a secondary benefit. It is the mechanism that keeps people using the product long enough to see the results the clinical data promises.